Advertisement

Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of outcomes

  • Shannon K. Rush
    Correspondence
    Corresponding author.
    Affiliations
    Department of Obstetrics & Gynecology, University of Wisconsin – Madison, 600 Highland Drive, Madison, WI 53792, United States of America
    Search for articles by this author
  • Brittany F. Lees
    Affiliations
    Department of Obstetrics & Gynecology, University of Wisconsin – Madison, 600 Highland Drive, Madison, WI 53792, United States of America

    Department of Obstetrics & Gynecology, Levine Cancer Institute at Atrium Health, 1021 Morehead Medical Drive, Suite 2100, Charlotte, NC 28204, United States of America
    Search for articles by this author
  • Dandi S. Huang
    Affiliations
    Department of Obstetrics & Gynecology, University of Wisconsin – Madison, 600 Highland Drive, Madison, WI 53792, United States of America

    Cedars Sinai Medical Center, Los Angeles, CA, United States of America
    Search for articles by this author
  • Megan F. Peterson
    Affiliations
    Department of Obstetrics & Gynecology, University of Wisconsin – Madison, 600 Highland Drive, Madison, WI 53792, United States of America
    Search for articles by this author
  • Ahmed Al-Niaimi
    Affiliations
    Department of Obstetrics & Gynecology, University of Wisconsin – Madison, 600 Highland Drive, Madison, WI 53792, United States of America
    Search for articles by this author
Published:September 13, 2022DOI:https://doi.org/10.1016/j.ygyno.2022.08.023

      Highlights

      • Splenectomy adds morbidity to ovarian cancer surgery, but is beneficial if aids in complete cytoreduction.
      • Splenectomy was associated with longer surgery and hospital length of stay, as well as more blood transfusions.
      • Splenectomy was not associated with increased post-operative infection, readmission, or decreased overall survival.
      • Splenectomy quality improvement should focus on vaccinations, discharge instructions, and pancreatic fistula recognition.

      Abstract

      Objectives

      We describe post-operative complications after cytoreductive surgery with and without splenectomy for Stage III or IV epithelial ovarian cancer, and identify areas for quality improvement in post-splenectomy care.

      Methods

      All patients with ovarian cancer cytoreductive surgery from 2008 to 2018 were identified using an institutional database Gynecologic Oncology Longitudinal Data Collection and Utilization Program (GOLD CUP). We compared patients who had and did not have splenectomy as part of cytoreductive surgery by demographics, comorbidities, stage, operative and post-operative data, readmission rates, progression free survival, overall survival and death from disease. Quality metrics reported include receipt of post-splenectomy education handouts and encapsulated-organism vaccines. Statistical analysis was completed in STATA SE 16.0.

      Results

      We identified 47 patients who underwent splenectomy and 454 who did not during primary or interval cytoreductive surgery. Final stage was IIIB in 1 (2.1%), IIIC in 26 (55.3%), IVA in 7 (14.9%), and IVB in 13 (27.7%) patients. Those with splenectomy had significantly higher stage. Surgery duration and hospital length of stay were longer and blood transfusion more common after splenectomy, but there were no differences in post-operative infection, readmission, or overall survival. Pancreatic leaks were seen in 4/47 (8.5%) patients. Post-splenectomy vaccinations were documented in 42/47 (89.4%) patients. Only 2/47 (4.3%) received post-splenectomy discharge instructions and 3/7 (42.9%) received aspirin for platelets 1 million or more.

      Conclusions

      While splenectomy adds morbidity, it continues to offer benefit in those patients who can achieve optimal cytoreduction. Areas for quality improvement in post-splenectomy care include receipt of vaccinations, patient discharge information, and timely pancreatic fistula management.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • U.S. Cancer Statistics Working Group
        U.S. Cancer Statistics Data Visualizations Tool, Based on 2019 Submission Data (1999–2017). U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute.
        (Published. Accessed June 6, 2021)
        • Team TACS medical and editorial content
        Key Statistics for Ovarian Cancer.
        The American Cancer Society, 2020 (Published)
        • Bristow R.E.
        • Tomacruz R.S.
        • Armstrong D.K.
        • Trimble E.L.
        • Montz F.J.
        Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a Meta-analysis.
        J. Clin. Oncol. 2002; 20: 1248-1259https://doi.org/10.1200/JCO.20.5.1248
        • Vergote I.
        • Tropé C.G.
        • Amant F.
        • et al.
        Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
        N. Engl. J. Med. 2010; 363: 943-953https://doi.org/10.1056/nejmoa0908806
        • Vergote I.
        • Coens C.
        • Nankivell M.
        • et al.
        Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
        Lancet Oncol. 2018; 19: 1680-1687https://doi.org/10.1016/S1470-2045(18)30566-7
        • Rodriguez N.
        • Miller A.
        • Richard S.D.
        • et al.
        Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of gynecologic oncology group (GOG) 182.
        Gynecol. Oncol. 2013; 130: 487-492https://doi.org/10.1016/j.ygyno.2013.06.017
        • Buzelé R.
        • Barbier L.
        • Sauvanet A.
        • Fantin B.
        Medical complications following splenectomy.
        J. Visc. Surg. 2016; 153: 277-286https://doi.org/10.1016/j.jviscsurg.2016.04.013
        • Nicklin J.L.
        • Copeland L.J.
        • O’Toole R.V.
        • Lewandowski G.S.
        • Vaccarello L.
        • Havenar L.P.
        Splenectomy as part of Cytoreductive surgery for ovarian carcinoma.
        Gynecol. Oncol. 1995; 58: 244-247
        • Magtibay P.M.
        • Adams P.B.
        • Silverman M.B.
        • Cha S.S.
        • Podratz K.C.
        Splenectomy as part of cytoreductive surgery in ovarian cancer.
        Gynecol. Oncol. 2006; 102: 369-374https://doi.org/10.1016/j.ygyno.2006.03.028
        • Sun H.
        • Bi X.
        • Cao D.
        • et al.
        Splenectomy during cytoreductive surgery in epithelial ovarian cancer.
        Cancer Manag. Res. 2018; 10: 3473-3482https://doi.org/10.2147/CMAR.S172687
        • Xiang L.
        • Tu Y.
        • He T.
        • et al.
        Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer.
        J. Gynecol. Oncol. 2016; 27: 1-9https://doi.org/10.3802/jgo.2016.27.e62
        • Zapardiel I.
        • Peiretti M.
        • Zanagnolo V.
        • et al.
        Splenectomy as part of primary cytoreductive surgery for advanced ovarian cancer: a retrospective cohort study.
        Int. J. Gynecol. Cancer. 2012; 22: 968-973https://doi.org/10.1097/IGC.0b013e3182571479
        • Eisenkop S.M.
        • Spirtos N.M.
        • Lin W.C.M.
        Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer.
        Gynecol. Oncol. 2006; 100: 344-348https://doi.org/10.1016/j.ygyno.2005.08.036
        • Doherty G.M.
        Spleen.
        in: Hill M. Current Diagnosis and Treatment: Surgery. 14th ed. 2014
        • Diseases NC for I and R. Recommended Adult Immunization Schedule for ages 19 years or older, United States
        US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute.
        (Published 2021. Accessed December 10, 2021)
        • Aletti G.D.
        • Dowdy S.C.
        • Podratz K.C.
        • Cliby W.A.
        Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.
        Am. J. Obstet. Gynecol. 2007; 197: 676.e1-676.e7https://doi.org/10.1016/j.ajog.2007.10.495
        • Guyatt G.H.
        • Akl E.A.
        • Crowther M.
        • Gutterman D.D.
        • Schünemann H.J.
        Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: 7S-47Shttps://doi.org/10.1378/chest.1412S3
        • Guntupalli S.R.
        • Brennecke A.
        • Behbakht K.
        • et al.
        Safety and efficacy of Apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial.
        JAMA Netw. Open. 2020; 3: 1-12https://doi.org/10.1001/jamanetworkopen.2020.7410
        • Boxer M.A.
        • Braun J.
        • Ellman L.
        Thromboembolic risk of postsplenectomy thrombocytosis.
        Arch. Surg. 1978; 113: 808-809https://doi.org/10.1001/archsurg.1978.01370190030004
        • Tefferi A.
        • Szuber N.
        • Pardanani A.
        • et al.
        Extreme thrombocytosis in low-risk essential thrombocythemia: retrospective review of vascular events and treatment strategies.
        Am. J. Hematol. 2021; 96: E182-E184https://doi.org/10.1002/ajh.26137
        • Kato K.
        • Tate S.
        • Nishikimi K.
        • Shozu M.
        Management of pancreatic fistulas after a splenectomy as part of cytoreductive surgery for ovarian cancer.
        Int. J. Gynecol. Cancer. 2013; 23: 1506-1511https://doi.org/10.1097/IGC.0b013e3182a0fa66